Drugs that contain Varenicline Tartrate
1. Chantix patents expiration
CHANTIX Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6410550 | PF PRISM CV | Aryl fused azapolycyclic compounds |
May, 2020
(3 years ago) | |
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(1 year, 11 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6410550 (Pediatric) | PF PRISM CV | Aryl fused azapolycyclic compounds |
Nov, 2020
(3 years ago) | |
|
US6890927 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(1 year, 5 months ago) | |
|
US7265119 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-192) | Dec 16, 2019 |
| Pediatric Exclusivity(PED) | Aug 22, 2022 |
| M(M-183) | Aug 12, 2019 |
| M(M-144) | Oct 15, 2017 |
| M(M-143) | Oct 15, 2017 |
| M(M-237) | Feb 22, 2022 |
| M(M-105) | Jul 22, 2014 |
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
How can I launch a generic of CHANTIX before it's drug patent expiration?
More Information on Dosage
CHANTIX family patents
2. Tyrvaya patents expiration
TYRVAYA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504644 | OYSTER POINT PHARMA | Methods of increasing tear production |
Oct, 2035
(11 years from now) | |
| US10456396 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(11 years from now) | |
| US9597284 | OYSTER POINT PHARMA | Dry eye treatments |
Oct, 2035
(11 years from now) | |
| US9532944 | OYSTER POINT PHARMA | Methods of improving ocular discomfort |
Oct, 2035
(11 years from now) | |
| US11224598 | OYSTER POINT PHARMA | Methods of increasing lacrimal proteins |
Oct, 2035
(11 years from now) | |
| US9504645 | OYSTER POINT PHARMA | Pharmaceutical formulations for treating ocular conditions |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Market Authorisation Date: 15 October, 2021
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SPRAY;NASAL
How can I launch a generic of TYRVAYA before it's drug patent expiration?
More Information on Dosage
TYRVAYA family patents